Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Temozolomide-Induced Thrombocytopenia in Glioblastoma
NCT02227576Phase 2Terminated
- Sponsor
- CHU de Lille
- Start
- Jul 2014
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in Thrombocytopenia, sponsored by CHU de Lille. Primary endpoint: Proportion of patients receiving 100% of the planned TMZ dosage at 1 year. Started Jul 2014; status: terminated.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT02227576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227576.